The Overview: Role of Enhancer of Zeste Homolog 2 in Gastric Cancer Progression and Chemotherapy Resistance
Makaleler > Tam Makale · 2023
Yazarlar: Nalan Gülşen ÜNAL
Journal of Enterocolitis, Hakemsiz Dergi, Uluslararası, Ebsco, 2023, cilt 1, ss 52-55
DOI: 10.5152/jenterocolitis.2022.221932
Özet
Gastric cancer is a heterogeneous disease with the origin of familial and sporadic disease; gastric cancer initiation and progression are caused by various factors such as genetic, epigenetic, and environmental risk factors.Epigenetic alterations determine cell behavior by modulating the transcriptional availability of diverse parts of the genome through DNA methylation, chromatin modification, histone modifications, and non-coding RNAs.DNA methyltransferases catalyze DNA methylation, and epigenetic studies proposed that DNA methylation interacts with histone modifications resulting in a change in gene expression.The multiple crucial biological effects of EZH2 have been identified including signal transduction, DNA repair, cell division, and autophagy.Enhanced EZH2 expression is a biomarker of metastasis in various cancers, such as prostate, breast, hepatocellular carcinomas, colorectal cancer, lung cancer, and gastric cancer.It has been shown that non-coding RNAs, siRNAs, and pharmacological inhibition suppressed the malignant progression of gastric cancer via EZH2 regulation.In this review, we discuss the importance and roles of EZH2 in gastric cancer progression and chemotherapy resistance.